|
[1]Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association.Recommendation on antiviral therapy to hepatitis B/C virus related hepatocellular carcinoma[J].J Clin Hepatol, 2013, 29 (1) :5-9. (in Chinese) 中华医学会肝病学分会肝癌学组.HBV/HCV相关性肝细胞癌抗病毒治疗专家建议[J].临床肝胆病杂志, 2013, 29 (1) :5-9.
|
|
[2]COILLY A, ROCHE B, SAMUEL D.Current management and perspectives for HCV recurrence after liver transplantation[J].Liver Int, 2013, 33 (Suppl 1) :56-62.
|
|
[3] RODRIGUEZ-LUNA H, DOUGLAS DD.Natural history of hepatitis C following liver transplantation[J].Curr Opin Infect Dis, 2004, 17 (4) :363-371.
|
|
[4]SAMUEL D, FORNS X, BERENGUER M, et al.Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006) [J].J Hepatol, 2006, 45 (1) :127-143.
|
|
[5]WIESNER RH, SORRELL M, VILLAMIL F, et al.Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C[J].Liver Transpl, 2003, 9 (11) :s1-s9.
|
|
[6]BERENGUER M, AGUILERA V, PRIETO M, et al.Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression[J].J Hepatol, 2006, 44 (4) :717-722.
|
|
[7]VIVARELLI M, BURRA P, LA BARBA G, et al.Influence of steroids on HCV recurrence after liver transplantation:A prospective study[J].J Hepatol, 2007, 47 (6) :793-798.
|
|
[8]FILIPPONI F, CALLEA F, SALIZZONI M, et al.Double-blind comparison of hepatitis C histological recurrence Rate in HCV+liver transplant recipients given basiliximab+steroids or basiliximab+placebo, in addition to cyclosporine and azathioprine[J].Transplantation, 2004, 78 (10) :1488-1495.
|
|
[9]SEGEV DL, SOZIO SM, SHIN EJ, et al.Steroid avoidance in liver transplantation:meta-analysis and meta-regression of randomized trials[J].Liver Transpl, 2008, 14 (4) :512-525.
|
|
[10] FIRPI RJ, ZHU H, MORELLI G, et al.Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation[J].Liver Transpl, 2006, 12 (1) :51-57.
|
|
[11]INOUE K, SEKIYAMA K, YAMADA M, et al.Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C:controlled trial[J].J Gastroenterol, 2003, 38 (6) :567-572.
|
|
[12] BERENGUER M, ROYUELA A, ZAMORA J.Immunosuppression withcalcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation:results of a meta-analysis[J].Liver Transpl, 2007, 13 (1) :21-29.
|
|
[13]STRAUSS G, HANSEN BA, KNUDSEN GM, et al.Hyperventilation restores cerebral blood fl ow autoregulation in patients with acute liver failure[J].J Hepatol, 1998, 28 (2) :199-203.
|
|
[14] BERENGUER M, ROYUELA A, ZAMORA J.Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation:results of a meta-analysis[J].Liver Transpl, 2007, 13 (1) :21-29.
|
|
[15]SHENOY S, HARDINGER KL, CRIPPIN J, et al.A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients[J].Liver Transpl, 2008, 14 (2) :173-180.
|
|
[16] SAMONAKIS DN, TRIANTOS CK, THALHEIMER U, et al.Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation[J].Liver Transpl, 2005, 11 (4) :386-395.
|
|
[17]BERENGUER M, PRIETO M, SAN JF, et al.Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients[J].Hepatology, 2002, 36 (1) :202-210.
|
|
[18]BAIOCCHI L, ANGELICO M, PETROLATI A, et al.Correlation between liver fibrosis and inflammation in patients transplanted for HCV liver disease[J].Am J Transplant, 2008, 8 (3) :673-678.
|
|
[19]EID AJ, BROWN RA, PAYA CV, et al.Associationbetween toll-like receptor polymorphisms and the outcome of liver transplantation for chronic hepatitis C virus[J].Transplantation, 2007, 84 (4) :511-516.
|
|
[20]WALTER T, DUMORTIER J, GUILLAUD O, et al.Rejection under alpha interferon therapy in liver transplant recipients[J].Am J Transplant, 2007, 7 (1) :177-184.
|
|
[21]BYTZER P, TALLEY NJ, JONES MP, et al.Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus[J].Aliment Pharmacol Ther, 2001, 15 (1) :137-142.
|
|
[22]WIESNER R, RABKIN J, KLINTMALM G, et al.A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients[J].Liver Transpl, 2001, 7 (5) :442-450.
|
|
[23]KORNBERG A, KUPPER B, TANNAPFEL A, et al.Impact of mycophenolate mofetil versus azathioprine on early recurrence of hepatitis C after liver transplantation[J].Int Immunopharmacol, 2005, 5 (1) :107-115.
|
|
[24]de RUVO N, CUCCHETTI A, LAURO A, et al.Preliminary results of a“prope”tolerogenic regimen with thymoglobulin pretreatment and hepatitis C virus recurrence in liver transplantation[J].Transplantation, 2005, 80 (1) :8-12.
|
|
[25]KAMAR N, BORDE JS, SANDRES-SAUNE K, et al.Induction therapy with either anti-CD25 monoclonal antibodies or rabbit antithymocyte globulins in liver transplantation for hepatitis C[J].Clin Transplant, 2005, 19 (1) :83-89.
|
|
[26]RAMIREZ CB, DORIA C, di FRANCESCO F, et al.Basiliximab induction in adult liver transplant recipients with 93%rejectionfree patient and graft survival at 24 months[J].Transplant Proc, 2006, 38 (10) :3633-3635.
|
|
[27]CARBONE M, LENCI I, BAIOCCHI L.Prevention of hepatitis C recurrence after liver transplantation:An update[J].World J Gastrointest Pharmacol Ther, 2012, 3 (4) :36-48.
|
|
[28]EVERSON GT, TERRAULT NA, LOK AS, et al.The Adult-to-Adult Living Donor Liver Transplantation Cohort Study.A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation[J].Hepatology, 2012, 57 (5) :1752-1762.
|
|
[29]BECKEBAUM S, KABAR I, CICINNATI VR.Hepatitis B and C in liver transplantation:new strategies to combat the enemies[J].Rev Med Virol, 2013, 23 (3) :172-193.
|
|
[30]MUTIMER D.Understanding the switchbacks:the impact of direct antivirals on the minimization of hepatitis C virus recurrence after transplantation[J].Liver Transpl, 2012, 18 (Suppl 2) :s47-s51.
|
|
[31]RABIE R, MUMTAZ K, RENNER EL.Efficacy of antiviral therapy for hepatitis C after liver transplantation with cyclosporine and tacrolimus:a systematic review and meta-analysis[J].Liver Transpl, 2013, 19 (1) :36-48.
|
|
[32] FONTANA RJ, HUGHES EA, APPELMAN H, et al.Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation[J].Liver Transpl, 2012, 18 (9) :1053-1059.
|
DownLoad: